Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
Tuberculose in Europa bij moeilijk bereikbare groepen
sep 2020 | Bacteriële infecties, Tuberculose